This article is more than 5 years old. Information may no longer be current.
VIDEO: Top take-aways in IBD therapies presented at DDW
Click Here to Manage Email Alerts
CHICAGO — In this exclusive video from Digestive Disease Week, William J. Sandborn, MD, professor of medicine, chief of the division of gastroenterology and director of the University of California San Diego Inflammatory Bowel Disease Center, recaps the most significant advances in biologic therapies for inflammatory bowel disease presented at the meeting.
First, results from “the CALM trial showed that adjusting biologic therapy using a treat-to-target strategy to resolve or normalize biomarkers of fecal calprotectin and lactoferrin led to much higher endoscopy healing rates and deep remission rates than just treating clinical symptoms using biologic therapy with adalimumab [Humira, AbbVie], so that was very exciting,” he said.
Developments in Janus kinase (JAK) inhibitors were also significant, he added.
“The pivotal phase 3 study of tofacitinib [Xeljanz, Pfizer] ... showed that tofacitinib was effective for maintaining remission in ulcerative colitis over 52 weeks at both 5- and 10-mg doses and had an acceptable safety profile,” and the results of the CELEST trial of upadacitinib (ABT-494, AbbVie) in Crohn’s disease “showed both clinical and endoscopic remission and response in a very refractory patient population who’d failed anti-TNF drugs and a third of whom had failed vedolizumab [Entyvio, Takeda].”
Finally, a presentation on the IL-23 inhibitor risankizumab (AbbVie) showed “long-term extension data with very high long-term remission rates up in the 50% range with long-term therapy, again in an anti-TNF failure population,” he said.
Reference:
Colombel JF, et al. Abstract #718. Presented at: Digestive Disease Week; May 6-9, 2017; Chicago.
Sandborn WJ, et al. Abstract #1080. Presented at: Digestive Disease Week; May 6-9, 2017; Chicago.
Sandborn WJ, et al. Abstract #874h. Presented at: Digestive Disease Week; May 6-9, 2017; Chicago.
Feagan BG, et al. Abstract #874l. Presented at: Digestive Disease Week; May 6-9, 2017; Chicago.
Disclosures: Sandborn reports a financial relationship with AbbVie, and numerous other relevant financial disclosures that can be found at ddw.org.